• For readers wondering whether Healthpeak Properties at around US$21.23 is trading at a bargain or already pricing in its prospects, this article breaks down what the current share price might be implying.
• The stock has recently moved by 8.5% over the last week, 6.0% over the past month, 31.0% year to date, 30.1% over one year, 28.9% over three years, and has declined 15.8% over five years. This gives a mixed picture for investors weighing potential and risk.
• Recent attention on Healthpeak Properties reflects ongoing interest in U.S. health care real estate and how listed REITs are responding to sector specific trends and capital market conditions. For investors, this context helps frame whether the recent share price path aligns with the underlying assets and balance sheet or has moved ahead of fundamentals.
• Simply Wall St currently assigns Healthpeak Properties a valuation score of 2 out of 6. The next sections will walk through the main valuation approaches behind that score and then finish with a broader framework that can help you interpret valuation signals more effectively.

Healthpeak Properties scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Healthpeak Properties Discounted Cash Flow (DCF) Analysis

The DCF model for Healthpeak Properties estimates what the stock could be worth by projecting adjusted funds from operations into the future and discounting those cash flows back to today in dollar terms. It focuses on what the company may generate for shareholders rather than short term earnings swings.

Healthpeak Properties is modelled using a 2 stage Free Cash Flow to Equity approach based on Adjusted Funds From Operations. The latest twelve month free cash flow is reported at $1.29b. Analyst estimates underpin cash flow projections out to 2030, with Simply Wall St extrapolating beyond the explicit analyst horizon to build a ten year path of future free cash flows and discounting each year back to today.

On this basis, the DCF model arrives at an estimated intrinsic value of $34.62 per share. Compared with the recent share price of about $21.23, this implies the stock is trading at a 38.7% discount to that intrinsic value, which indicates that Healthpeak Properties appears undervalued on this specific cash flow based approach.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Healthpeak Properties is undervalued by 38.7%. Track this in your watchlist or portfolio, or discover 43 more high quality undervalued stocks.

Approach 2: Healthpeak Properties Price vs Earnings

For profitable companies like Healthpeak Properties, the P/E ratio is a useful way to link what you pay for each share to the earnings that support that price. Investors usually expect higher P/E ratios when they see stronger growth potential or lower risk, and lower P/E ratios when growth looks more modest or risks are higher.

Healthpeak Properties currently trades on a P/E of 66.0x. This compares with an industry average P/E for Health Care REITs of 20.0x and a peer group average of 43.0x, so the stock is valued more richly than both its sector and close comparables on this metric.

Simply Wall St also provides a proprietary “Fair Ratio” of 28.6x for Healthpeak Properties. This aims to estimate what a reasonable P/E might be after considering factors such as the company’s earnings growth profile, industry, profit margins, market capitalization and risk characteristics. Because it adjusts for these elements, the Fair Ratio can give a more tailored benchmark than a simple comparison with peers or the wider industry. With the current P/E of 66.0x versus the Fair Ratio of 28.6x, the shares appear expensive on this framework.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Healthpeak Properties Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Meet Narratives, a simple framework on Simply Wall St's Community page that lets you attach a clear story about Healthpeak Properties to your numbers by linking your view of its future revenue, earnings and margins to a financial forecast, a Fair Value estimate and then a comparison with the current share price, which is refreshed automatically as new news or earnings arrive.

In practice, one investor might build a cautious Healthpeak Properties Narrative that lines up with the bearish Fair Value of US$17.00, assuming revenue declines of about 8.0% a year, shrinking profit margins toward 3.4% and a future P/E of about 189.9x. Another might prefer a more upbeat Narrative closer to the bullish Fair Value of about US$25.80, using revenue growth of roughly 4.8% a year, margin expansion toward 8.8% and a future P/E near 80.0x. By setting out these different stories side by side you can judge which assumptions feel more realistic for you and see how that translates into a personal view on whether Healthpeak Properties looks cheap or expensive today.

For Healthpeak Properties however we will make it really easy for you with previews of two leading Healthpeak Properties Narratives:

Fair value: US$25.80

Implied discount to fair value: 17.7% based on the recent share price of about US$21.23.

Revenue growth assumption: 4.79% a year.

• Focuses on higher margins supported by AI driven property management and technology upgrades that aim to improve operational efficiency and tenant retention across the portfolio.
• Sees long run support from senior housing exposure and outpatient medical facilities tied to an aging U.S. population and limited new supply.
• Assumes earnings and profit margins rise over time, with valuation supported by a higher future P/E multiple than the wider U.S. Health Care REITs group.

Fair value: US$17.00

Implied premium to fair value: 24.9% based on the recent share price of about US$21.23.

Revenue growth assumption: revenue is assumed to decline 7.98% a year.

• Highlights tenant risk in life science properties, particularly smaller biotech companies that rely heavily on capital markets and could pressure occupancy and cash flow.
• Points to geographic concentration, development execution risk and refinancing costs as potential drags on net margins and balance sheet flexibility.
• Builds in shrinking profit margins and lower earnings over time, with a high future P/E multiple required to support the bearish price target.

If you want to see how other investors are weighing these different assumptions and how they update their views as new data comes through, See what the community is saying about Healthpeak Properties.

Do you think there's more to the story for Healthpeak Properties? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.